Advertisement
Epitomics
Epitomics

Most Recent

image: Short, Strong Signals

Short, Strong Signals

By | March 25, 2015

Methylation increases both the activity and instability of the signaling protein Notch.

0 Comments

image: AbbVie Wins Bidding War for Cancer Drugmaker

AbbVie Wins Bidding War for Cancer Drugmaker

By | March 5, 2015

The pharmaceutical firm beat out a host of potential suitors, Johnson & Johnson among them, to strike a $21 billion deal with Pharmacyclics.

0 Comments

image: Capsule Reviews

Capsule Reviews

By | March 1, 2015

Evolving Ourselves, The Man Who Touched His Own Heart, Bats, and The Invaders

0 Comments

image: Shire Makes $5.2 Billion Buy

Shire Makes $5.2 Billion Buy

By | January 13, 2015

The Irish drugmaker moves on from its terminated sale to AbbVie to purchase New Jersey-based NPS Pharmaceuticals.

0 Comments

image: Spinoff Company to Develop Rare Disease Drugs

Spinoff Company to Develop Rare Disease Drugs

By | January 7, 2015

Maryland-based Vtesse will work with the US National Institutes of Health to advance treatments for Niemann-Pick Type C disease and other lysosomal storage disorders.

0 Comments

image: Fertility Treatment Fallout

Fertility Treatment Fallout

By | January 1, 2015

Mouse offspring conceived by in vitro fertilization are metabolically different from naturally conceived mice.

7 Comments

image: Taming Bushmeat

Taming Bushmeat

By | January 1, 2015

Chinese farmers’ efforts at rearing wild animals may benefit conservation and reduce human health risks.

1 Comment

image: Bats Make a Comeback

Bats Make a Comeback

By | December 22, 2014

Citizen-scientist data obtained through the U.K.’s National Bat Monitoring Programme show that populations of 10 bat species have stabilized or are growing.

0 Comments

image: NIH Study Canceled

NIH Study Canceled

By | December 15, 2014

The National Institutes of Health shutters its initiative to track the health of 100,000 children through adulthood.

3 Comments

image: Merck Buys Cubist for $8.4B

Merck Buys Cubist for $8.4B

By | December 11, 2014

Hours after the pharmaceutical giant announced the acquisition, a federal judge invalidated key patents behind the antibiotic maker’s most lucrative product.

0 Comments

Follow The Scientist

icon-facebook icon-linkedin icon-twitter icon-vimeo icon-youtube
Advertisement
EMD Millipore
EMD Millipore

Stay Connected with The Scientist

  • icon-facebook The Scientist Magazine
  • icon-facebook The Scientist Careers
  • icon-facebook Neuroscience Research Techniques
  • icon-facebook Genetic Research Techniques
  • icon-facebook Cell Biology Research
  • icon-facebook Microbiology and Immunology
  • icon-facebook Cancer Research and Technology
  • icon-facebook Stem Cell and Regenerative Science
Advertisement
The Scientist
The Scientist
Advertisement